4 completed, 2 terminated, 1 recruiting, 1 unknown. 9 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Terminated 2, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Neoplasms, Second Primary: new trials by email Literature Review of Neoplasms, Second Primary trials Research Report on Neoplasms, Second Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PREventing Second Cancers With DOSTARlimab Dostarlimab - Recurrent Cancer, Primary Cancer | Phase 2 | Recruiting | Centre Leon Berard | 400 | 2023-07-26 | 2024-07-15 |
| Signal TrAnsduction Pathway Activity Analysis in OVarian cancER Letrozole Oral Product, Bicalutamide Oral Product, Everolimus Oral Product - Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation | Phase 2 / Phase 3 | Unknown | Gynaecologisch Oncologisch Centrum Zuid | 148 | 2023-01-31 | 2023-04-18 |
| Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment Varenicline, Bupropion, Long-acting nicotine replacement therapy - Smoking Cessation, Cancer, Treatment-Related | Phase 2 | Completed | Joseph Valentino, MD | 126 | 2021-01-12 | 2026-02-02 |
| FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC 5-FU, Folinic Acid, Irinotecan - Treatment Related Cancer | Phase 2 | Completed | Ludwig-Maximilians - University of Munich | 57 | 2019-09-27 | 2025-04-16 |
| Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation Panitumumab, Irinotecan, Folinic acid - Treatment Related Cancer | Phase 2 | Terminated | Ludwig-Maximilians - University of Munich | 3 | 2019-07-24 | 2026-08-27 |
| Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia Ex Vivo-activated Autologous Lymph Node Lymphocytes, Laboratory Biomarker Analysis - Anemia, Cancer Fatigue | Phase 2 | Completed | M.D. Anderson Cancer Center | 8 | 2015-12-18 | 2019-10-29 |
| Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) temozolomide - Breast Neoplasm, Brain Neoplasm | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 6 | 2008-10-02 | 2017-06-14 |
| DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer Radiotherapy - Head and Neck Neoplasms, Recurrence | Phase 2 | Completed | University of Aarhus | 100 | 2006-11-01 | 2013-06-19 |
| Clonidine for Neurocognitive Sequelae Clonidine - Treatment-Related Cancer | Phase 1 / Phase 2 | Withdrawn | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 2013-01-11 |
Neoplasms (2) · Recurrence (2) · Anemia (1) · Behavior, Addictive (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Communicable Diseases (1) · Fever (1) · Head and Neck Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic (1) · Lymphadenopathy (1) · Lymphocytosis (1)
Neoplasms (7) · Neoplasms by Site (4) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Adnexal Diseases (1) · Behavior (1) · Blood Platelet Disorders (1) · Body Temperature Changes (1) · Body Weight (1) · Body Weight Changes (1) · Brain Diseases (1) · Breast Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1)
Fluorouracil (2) · Irinotecan (2) · Leucovorin (2) · Bupropion (1) · Cetuximab (1) · Clonidine (1) · Nicotine Chewing Gum (1) · Panitumumab (1) · Radiotherapy (1) · Temozolomide (1) · Tobacco Use Cessation Devices (1) · Varenicline (1) · avelumab (1) · dostarlimab (1)
Ludwig-Maximilians - University of Munich (2) · Centre Leon Berard (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Gynaecologisch Oncologisch Centrum Zuid (1) · Joseph Valentino, MD (1) · M.D. Anderson Cancer Center (1) · Merck Sharp & Dohme LLC (1) · University of Aarhus (1)
United States (3) · Germany (2) · Denmark (1) · France (1) · Netherlands (1)
Dominik Modest, PD Dr. (2) · Chitra Hosing (1) · Joseph Valentino, MD (1) · Kenneth Jensen, MD (1)
P30CA016672 (1)